AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy.
This study aimed to examine the most reliable evidence on the relationship between early menopause and the risk of heart failure and atrial fibrillation.
GeneFirst Ltd announced the release of Papilloplex HR-HPV to be marketed as a CE-IVD product under the European Directive on...
Pfizer Inc. announced two additional Phase III RN 316 (bococizumab) trials, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary...
Daiichi Sankyo announced that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Gilead Sciences announced longer-term overall survival (OS) results from the Phase III TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies
Eli Lilly and Company has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2(HER2) negative, node-positive Early Breast Cancer (EBC) at high risk of recurrence
Abemaciclib, a CDK4/6 inhibitor, is the first adjuvant in 16 years to be added to endocrine therapy for HR+/HER2− early breast cancer and the first of its class to receive FDA and EMA approval for this indication.
Gilead Sciences, Inc. has announced the FDA has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
The European Commission has approved Afinitor (everolimus) tablets from Novartis for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced...